Mercado mundial de pruebas de inmunoabsorción ligada a enzimas (ELISA): tendencias de la industria y pronóstico hasta 2031

Análisis y tamaño del mercado de pruebas de inmunoabsorción ligada a enzimas (ELISA)

La creciente prevalencia de enfermedades infecciosas , como el VIH/SIDA, la hepatitis y la enfermedad de Lyme, está impulsando la demanda de pruebas ELISA para un diagnóstico temprano y preciso. La creciente prevalencia de enfermedades infecciosas, como lo destacan los datos de la OMS actualizados en julio de 2022, ha llevado a una mayor demanda de herramientas de diagnóstico como la prueba ELISA. Se estima que 37,7 millones de personas vivían con VIH en todo el mundo a fines de 2020, y más de dos tercios de ellas (25,6 millones) residían en la región africana. Además, el dengue se ha convertido en una de las diez principales amenazas para la salud mundial, con un aumento de 30 veces en la incidencia mundial en los últimos 50 años. Las actualizaciones de la Organización Mundial de la Salud de junio de 2022 indican que más de 354 millones de personas en todo el mundo están afectadas por infecciones de hepatitis B o C. Esta creciente incidencia de enfermedades infecciosas subraya la creciente necesidad de un diagnóstico preciso y oportuno.

El tamaño del mercado mundial de pruebas de ensayo inmunoabsorbente ligado a enzimas (ELISA) se valoró en USD 2,52 mil millones en 2023 y se proyecta que alcance los USD 4,40 mil millones para 2031, con una CAGR del 7,23% durante el período de pronóstico de 2024 a 2031. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado       

Market Definition

ELISA (Enzyme-Linked Immunosorbent Assay) tests are a type of biochemical assay technique used to detect the presence of an antigen or antibody in a sample. This highly sensitive method relies on the interaction between an enzyme-linked antibody or antigen and a substrate to produce a measurable signal, typically a color change. ELISA tests are widely used in medical diagnostics, research laboratories, and the pharmaceutical industry for various purposes, including the detection of infectious diseases, monitoring of drug levels in the blood, and quantification of specific proteins.      

Enzyme-Linked Immunosorbent Assay (ELISA) Tests Market Dynamics

Drivers

• Increasing Prevalence of Chronic and Infectious Diseases 

The increasing prevalence of chronic and infectious diseases such as HIV/AIDS, hepatitis, cancer, and autoimmune disorders highlights the critical need for accurate and early diagnosis, a role in which ELISA tests excel. The GLOBOCAN 2020 report indicates that approximately 2,281,658 cases of cancer were recorded in the U.S. in 2020. This number is projected to increase to 3,123,452 cases by 2040. According to the National Diabetes Statistics Report, approximately 37.3 million individuals in the U.S. were diagnosed with diabetes in 2020, with approximately 96 million adults found to have pre-diabetes. As the burden of these diseases continues to rise worldwide, ELISA tests such as elisa test for hiv play a crucial role in disease management and monitoring, making them a fundamental tool in healthcare systems. These diseases require timely and precise monitoring for effective management and treatment, driving the demand for ELISA tests globally.

• Rising Demand for Early and Accurate Disease Diagnosis

There is a rising demand for early and accurate disease diagnosis across various medical fields. ELISA tests are renowned for their high sensitivity and specificity, making them indispensable for early disease detection and monitoring treatment efficacy and increasing application of elisa test. This growing demand for precise diagnostic tools is a major driver for the expansion of the ELISA tests market, as healthcare providers and patients alike seek reliable methods for detecting and managing diseases at their earliest stages.

Opportunities

• Development of Multiplex ELISA Assays   

Multiplex assays offer advantages such as reduced sample volume, lower costs, and increased efficiency, making them attractive for various clinical and research applications. The ability to simultaneously measure multiple biomarkers is particularly beneficial in disease profiling and personalized medicine. The development of multiplex ELISA assays, which can detect multiple analytes in a single sample, presents a significant opportunity for market growth.                

• Integration of Artificial Intelligence (AI) and Machine Learning 

The integration of AI and machine learning technologies in ELISA testing is poised to revolutionize the field. These technologies can improve assay performance, data analysis, and result interpretation, leading to more accurate and efficient ELISA tests. AI and machine learning can also help in identifying complex patterns and trends in large datasets, enhancing the diagnostic capabilities of ELISA test process and driving their adoption in clinical and research settings.

Restraints/Challenges

• High Cost of ELISA Tests

The cost associated with ELISA tests, especially for specialized assays and reagents, is a significant barrier to market growth. The high Elisa test cost may limit their adoption, particularly in resource-limited settings and for routine screening purposes. Efforts to reduce the cost of ELISA tests, such as the development of cost-effective assay kits and reagents, could help overcome this barrier and expand the market reach of ELISA testing.

• Availability of Alternative Technologies

 The availability of alternative technologies, such as PCR, next-generation sequencing, and point-of-care testing, poses a challenge to the ELISA tests market. These alternative technologies offer advantages such as faster turnaround times, higher sensitivity, and lower costs, which may limit the growth of the ELISA test market in certain applications. However, continued innovation and advancements in ELISA technology could help maintain its competitiveness in the diagnostic testing landscape.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In December 2022, bispecific antibodies emerged as a notable advancement in the field, targeting two epitopes simultaneously. This approach gained rapid traction among scientists and pharmaceutical manufacturers, with the US FDA and EMA approving four different BsAb drugs for therapeutic use. These bispecific antibodies are primarily aimed at cancer targets, specifically the CD3 pathways
• In September 2022, Neogen Corporation introduced its Veratox VIP assay for cashew detection, marking the second assay in the company's new Veratox VIP line of advanced quantitative ELISA products. Also in September 2022, J Mitra launched its 4th Generation Elisa-based HCV Test, named the HCV Gen 4 Ag & Ab Microlisa. This test is designed for the qualitative detection of HCV core antigen and antibodies against HCV (anti-HCVs) in human serum or plasma

Enzyme-Linked Immunosorbent Assay (ELISA) Tests Market Scope

The market is segmented on the basis of method, application, technology, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications. 

Method

• Direct ELISA
• Indirect ELISA
• Sandwich ELISA
• Competitive ELISA

Application

• Vaccine Development
• Immunology
• Diagnostics
• Toxicology
• Drug Monitoring and Pharmaceutical Industry
• Transplantation
• Infectious Diseases
• Cancer
• Protein Quantitation
• Others

Technology

• Chemiluminescent
• Colorimetric
• Fluorescent

End User

• Hospitals and Diagnostic Centers
• Research Laboratories

Enzyme-Linked Immunosorbent Assay (ELISA) Tests Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, method, application, technology, and end user as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

Se espera que América del Norte domine el mercado debido a

Se espera que Asia-Pacífico sea testigo de un crecimiento significativo durante el período de pronóstico debido a

La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Puntos de datos como análisis de la cadena de valor aguas abajo y aguas arriba, tendencias técnicas y análisis de las cinco fuerzas de Porter, estudios de casos son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas globales y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales se consideran al proporcionar un análisis de pronóstico de los datos del país.

Crecimiento de la infraestructura de atención de salud Base instalada y penetración de nuevas tecnologías

El mercado también le ofrece un análisis detallado del mercado para cada país: crecimiento del gasto sanitario en equipos de capital, base instalada de diferentes tipos de productos para el mercado, impacto de la tecnología mediante curvas de línea de vida y cambios en los escenarios regulatorios de la atención sanitaria y su impacto en el mercado. Los datos están disponibles para el período histórico 2016-2021.

Análisis del panorama competitivo y de la cuota de mercado de las pruebas de inmunoabsorción ligada a enzimas (ELISA)

El panorama competitivo del mercado proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y variedad de productos, y el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado.

Algunos de los principales actores que operan en el mercado son:

• • Diagnóstico ortoclínico (EE. UU.)
  • Thermo Fisher Scientific (Estados Unidos)
  • ZEUS Scientific, Inc. (Estados Unidos)
  • ALPCO (Estados Unidos)
  • BD (Estados Unidos)
  • Laboratorios Bio-Rad, Inc. (Estados Unidos)
  • bioMérieux SA (Francia)
  • Enzo Life Sciences, Inc. (Estados Unidos)
  • Merck KGaA (Alemania)
  • BioLegend, Inc. (Estados Unidos)
  • LOEWE Biochemica GmbH (Alemania)
  • Diagnóstico creativo (Estados Unidos)
  • Arigo biolaboratories Corp. (EE. UU.)
  • ELISA Technologies, Inc. (Estados Unidos)
  • RayBiotech, Inc. (Estados Unidos)
  • R&D Systems, Inc. (Estados Unidos)
  • AESKU.GROUP GmbH & Co. KG (Alemania)
  • Tecnología celular (EE.UU.)
  • Ensayos de árboles (EE. UU.)
  • Eurofins Scientific (Luxemburgo)
  • Biogenuix (India)
  • F. Hoffmann-La Roche Ltd (Suiza)
  • Abbott (Estados Unidos)
  • Danaher (Estados Unidos)
  • Corporación Sysmex (Japón)
  • PerkinElmer Inc. (Estados Unidos)
  • Agilent Technologies (Estados Unidos)

SKU-52683